Literature DB >> 8610016

A role for the proteasome regulator PA28alpha in antigen presentation.

M Groettrup1, A Soza, M Eggers, L Kuehn, T P Dick, H Schild, H G Rammensee, U H Koszinowski, P M Kloetzel.   

Abstract

Cytotoxic T cells recognize viral proteins as peptide fragments which are produced in the cytosol and transported on major histocompatibility complex (MHC) class I proteins to the cell surface. Viral peptides that meet the stringent binding characteristics of class I proteins are generated by the 20S proteasome. The interferon (IFN)-gamma-inducible activator of the 20S proteasome, PA28, strongly influences the proteasomal cleavage pattern in vitro. This led us to investigate whether changes in cellular levels of PA28 affect the efficiency of viral antigen processing. A mouse fibroblast line expressing the murine cytomegalovirus pp89 protein was transfected with either the human or murine gene encoding the PA28alpha subunit, which is sufficient to activate the peptide-hydrolysing activity of the 20S proteasome in vitro. Here we report that enhanced expression of PA28alpha at a level similar to that obtained after IFN-gamma induction resulted in a marked enhancement of recognition by pp89-specific cytotoxic T cells; the presentation of influenza nucleoprotein was also significantly improved. These results demonstrate a fundamental in vivo function for PA28alpha in antigen processing.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8610016     DOI: 10.1038/381166a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  90 in total

1.  gamma-Interferon decreases the level of 26 S proteasomes and changes the pattern of phosphorylation.

Authors:  S Bose; P Brooks; G G Mason; A J Rivett
Journal:  Biochem J       Date:  2001-01-15       Impact factor: 3.857

2.  Subcellular localization of proteasomes and their regulatory complexes in mammalian cells.

Authors:  P Brooks; G Fuertes; R Z Murray; S Bose; E Knecht; M C Rechsteiner; K B Hendil; K Tanaka; J Dyson; J Rivett
Journal:  Biochem J       Date:  2000-02-15       Impact factor: 3.857

3.  A kinetic model of vertebrate 20S proteasome accounting for the generation of major proteolytic fragments from oligomeric peptide substrates.

Authors:  H G Holzhütter; P M Kloetzel
Journal:  Biophys J       Date:  2000-09       Impact factor: 4.033

4.  PI31 is a modulator of proteasome formation and antigen processing.

Authors:  Dietmar M W Zaiss; Sybille Standera; Peter-M Kloetzel; Alice J A M Sijts
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-08       Impact factor: 11.205

5.  Synthetic peptide-based activators of the proteasome.

Authors:  S Wilk; W E Chen
Journal:  Mol Biol Rep       Date:  1997-03       Impact factor: 2.316

Review 6.  Degradation of damaged proteins: the main function of the 20S proteasome.

Authors:  Andrew M Pickering; Kelvin J A Davies
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

7.  A mathematical model of protein degradation by the proteasome.

Authors:  Fabio Luciani; Can Keşmir; Michele Mishto; Michal Or-Guil; Rob J de Boer
Journal:  Biophys J       Date:  2005-01-21       Impact factor: 4.033

8.  Three immunoproteasome-associated subunits cooperatively generate a cytotoxic T-lymphocyte epitope of Epstein-Barr virus LMP2A by overcoming specific structures resistant to epitope liberation.

Authors:  Yoshinori Ito; Eisei Kondo; Ayako Demachi-Okamura; Yoshiki Akatsuka; Kunio Tsujimura; Mitsune Tanimoto; Yasuo Morishima; Toshitada Takahashi; Kiyotaka Kuzushima
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

Review 9.  Polyfunctional analysis of human t cell responses: importance in vaccine immunogenicity and natural infection.

Authors:  George Makedonas; Michael R Betts
Journal:  Springer Semin Immunopathol       Date:  2006-08-25

Review 10.  The ubiquitin proteasome system and myocardial ischemia.

Authors:  Justine Calise; Saul R Powell
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-12-07       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.